Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year

JAMA. 2017 Mar 14;317(10):1075-1077. doi: 10.1001/jama.2016.20644.

Authors

Rebecca L Winslow¹, Iain D Milligan¹, Merryn Voysey², Kerstin Luhn³, Georgi Shukarev³, Macaya Douoguih³, Matthew D Snape¹

Affiliations

¹ Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
² Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
³ Janssen, Leiden, the Netherlands.

PMID: 28291882
DOI: 10.1001/jama.2016.20644

No abstract available

Publication types

Clinical Trial, Phase I
Randomized Controlled Trial

MeSH terms

Adenoviridae / immunology*
Adult
Antibodies, Viral / blood
Ebola Vaccines / immunology*
Female
Follow-Up Studies
Glycoproteins
Hemorrhagic Fever, Ebola / immunology*
Hemorrhagic Fever, Ebola / prevention & control
Humans
Immunity, Cellular
Immunization Schedule*
Immunization, Secondary
Male
Single-Blind Method
T-Lymphocytes / immunology
Time Factors
Vaccinia virus / immunology*
Viral Proteins / immunology

Substances

Antibodies, Viral
Ebola Vaccines
Glycoproteins
Viral Proteins